Literature DB >> 2643454

Diagnosis of major tumor categories in fine-needle aspirates is more accurate when light microscopy is combined with intermediate filament typing. A study of 403 cases.

W Domagala1, J Lasota, M Chosia, A Szadowska, K Weber, M Osborn.   

Abstract

Intermediate filament (IF) typing of tumor cells with monoclonal antibodies was applied to 403 fine-needle aspirates. In 271 cases specific cytologic diagnosis of tumor type was apparent from clinical data and light microscopic study alone. Intermediate filament typing confirmed the tumor type in 262 cases and changed an erroneous cytologic diagnosis of major tumor type in nine cases. In a second group of 132 difficult cases, where the tumor type could not be revealed with certainty, IF typing confirmed the cytologic suggestion of tumor type in 50 cases, changed it in nine cases, and helped resolve ambiguities in cytologic diagnosis in 59 cases. It did not help in 14 cases. Thus IF typing adds independent objective differentiation specific information to descriptive tumor typing currently used in aspiration cytologic study. When combined with the morphologic analysis of tumor cells and clinical information it can refine the cytologic diagnosis of major tumor types and prevent error.

Entities:  

Mesh:

Year:  1989        PMID: 2643454     DOI: 10.1002/1097-0142(19890201)63:3<504::aid-cncr2820630319>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.

Authors:  W Domagala; J Lasota; J Bartkowiak; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

2.  Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.

Authors:  W Domagala; J Lasota; A Dukowicz; M Markiewski; G Striker; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.